Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin
| Autor: | Dimpal A Nyayanit, Kamran Zaman, Samiran Panda, Rajni Kant, Sandeep Chaowdhary, Rima R Sahay, Himanshu Kaushal, Balram Bhargava, Nivedita Gupta, Gaurav Dwivedi, Gajanan Sapkal, Pragya D Yadav, Priya Abraham, Sanjay Kumar, Rajeev Singh, Gururaj Deshpande |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
COVID-19 Vaccines
Heterologous Priming (immunology) ChAdOx1 nCoV-19 Research Letter Humans Medicine Adverse effect Neutralizing antibody biology SARS-CoV-2 business.industry Immunogenicity COVID-19 Immunogenecity General Medicine Virology Covishield Vaccination Regimen Vaccines Inactivated Immunization Heterologous regime Covaxin biology.protein business AcademicSubjects/MED00295 |
| Zdroj: | Journal of Travel Medicine |
| ISSN: | 1708-8305 1195-1982 |
| Popis: | The evidence for effectiveness of heterologous priming of COVID-19 vaccine is very limited. Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca’s ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. Heterologous group participant doesn’t report any adverse event following immunization and demonstrated high humoral and neutralizing antibody response. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|